TELA Bio president granted options and RSUs

TELA Bio, Inc. President Jeffrey Blizard reported equity awards consisting of stock options and restricted stock units granted on February 20, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TELA Bio, Inc. President Jeffrey Blizard reported equity awards consisting of stock options and restricted stock units granted on February 20, 2026. He was granted stock options for 127,000 shares at an exercise price of $0.00 per share and a separate award of 86,000 shares of common stock in the form of restricted stock units.

The restricted stock units will vest in four equal annual installments beginning on February 20, 2027, contingent on his continuous service through each vesting date. The stock option will vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, also subject to continued service.

Insider Trade Summary

Grant/Award: 213,000 shares

Grant/Award 2 txns

Insider Blizard Jeffrey

Role President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	127,000	$0.00	$0.00
Grant/Award	Common Stock	86,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 127,000 contracts (Direct); Common Stock — 205,125 shares (Direct)

Footnotes (2)

F1. These restricted stock units will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.
F2. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did TELA (TELA) President Jeffrey Blizard receive?

Jeffrey Blizard received stock options for 127,000 shares at $0.00 per share and 86,000 restricted stock units of TELA Bio common stock. Both awards were granted on February 20, 2026 as part of his compensation package, subject to multi-year vesting conditions tied to continued service.

How do Jeffrey Blizard’s 127,000 TELA stock options vest?

The 127,000 stock options vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. Vesting is conditioned on Blizard’s continued service with TELA Bio through each applicable vesting date over that period.

What is the vesting schedule for Jeffrey Blizard’s 86,000 restricted stock units in TELA?

The 86,000 restricted stock units vest in four equal annual installments starting February 20, 2027. Each 25% tranche requires Jeffrey Blizard to remain in continuous service with TELA Bio through the respective vesting date before the related common shares are delivered.

Did Jeffrey Blizard buy TELA Bio shares on the open market in this Form 4?

No, the Form 4 reports grants of stock options and restricted stock units at $0.00 per share, not open-market purchases. These awards represent equity compensation granted by TELA Bio, contingent on future service and subject to the specified vesting schedules over several years.

How many TELA Bio common shares does Jeffrey Blizard hold after these awards?

Following the restricted stock unit award, Jeffrey Blizard’s reported direct holdings of TELA Bio common stock total 205,125 shares. The 127,000 stock options are reported separately as derivative securities, giving him rights to acquire additional shares if the options fully vest and are exercised.

What conditions could affect Jeffrey Blizard’s ability to receive all granted TELA equity?

Both the restricted stock units and stock options require Jeffrey Blizard’s continuous service with TELA Bio through future vesting dates. If his service ends before those dates, unvested portions may be forfeited under the award terms, limiting how many shares he ultimately receives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/24/2026 - 08:00 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blizard Jeffrey

(Last)

(First)

(Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN

19355

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		A		86,000⁽¹⁾	A	$0	205,125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.717	02/20/2026		A		127,000		⁽²⁾	02/20/2036	Common Stock	127,000	$0	127,000	D

Explanation of Responses:

1. These restricted stock units will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.

2. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

	/s/ Megan Smeykal, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR